Up to 2022, Novo Nordisk expects to hire 6,000 new
employees in Denmark, half of whom will work within research and development. The new jobs will have the derived effect of boosting employment by more than 15,000 jobs
nationally. This is revealed by a new analysis to be presented by Novo Nordisk today at the 'Invitation to growth - a road to job creation' conference. The analysis homes in on the value created in the interaction between growth businesses and public-sector research and education, as well as the challenges that must be solved so that research-based businesses can continue to grow in Denmark.
"With the expectation of creating 6,000 new jobs in Denmark over the coming years, it will be crucial for Novo Nordisk that Denmark educates world-class graduates but also focuses far more intently on attracting international talent,” says Executive Vice President and Chief Science Officer Mads Krogsgaard Thomsen.
The analysis presents new forecasts for the future availability of university graduates and PhDs and questions whether Denmark is investing sufficiently in the frameworks that are necessary for providing strong research-based degree programmes.
The conference is being hosted today by Novo Nordisk from 12.30 to 16.30 at the company's headquarters in Bagsværd. The debaters will include Danish Minister for Higher Education and Science Sofie Carsten Nielsen; Chair of the Government's Expert Committee on Quality in Higher Education Jørgen Søndergaard; Rector of the University of Copenhagen Ralf Hemmingsen; and the political spokespersons for the Liberal Party of Denmark and the Danish Social Democrats.
The analysis is available at novonordisk.com; photos and b-roll from Novo Nordisk's Research & Development department are also available for download from novonordisk.com.
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 40,000 employees in 75 countries, and markets its products in more than 180 countries.